Allogene Therapeutics
ALLO
170 hedge funds and large institutions have $398M invested in Allogene Therapeutics in 2023 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 50 increasing their positions, 52 reducing their positions, and 22 closing their positions.
77% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 22
10% more funds holding
Funds holding: 154 → 170 (+16)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less capital invested
Capital invested by funds: $413M → $398M (-$15.5M)
4% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 52
4.09% less ownership
Funds ownership: 77.73% → 73.64% (-4.1%)
79% less call options, than puts
Call options by funds: $96K | Put options by funds: $451K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.54M |
| 2 |
Goldman Sachs
New York
|
+$5.47M |
| 3 |
Millennium Management
New York
|
+$5.09M |
| 4 |
BlackRock
New York
|
+$3.14M |
| 5 |
Two Sigma Investments
New York
|
+$2.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$16.4M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$14.2M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$7.76M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.42M |
| 5 |
Rafferty Asset Management
New York
|
-$1.92M |
ALLO Hedge Fund Activity: Q4 2023 in Review
170 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2023, worth a combined $398M — down 3.8% from $413M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new ALLO positions and 22 closed out — a net gain of 17 holders — while 50 added to existing stakes and 52 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $5.54M. The largest seller was State Street, cutting an estimated $16.4M.
- 170 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2023, up from 154 in Q3 2023.
- Funds reported $398M of Allogene Therapeutics stock for Q4 2023, down 3.8% quarter-over-quarter.
- 39 funds opened new Allogene Therapeutics positions in Q4 2023 and 22 closed out, a net change of +17 holders.
- The largest Allogene Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $5.54M added.
- The largest Allogene Therapeutics seller in Q4 2023 was State Street, an estimated $16.4M sold.
Based on aggregated 13F filings for Q4 2023.